{"protocolSection":{"identificationModule":{"nctId":"NCT03811574","orgStudyIdInfo":{"id":"NN9536-4382"},"secondaryIdInfos":[{"id":"U1111-1201-1629","type":"OTHER","domain":"World Health Organization (WHO)"}],"organization":{"fullName":"Novo Nordisk A/S","class":"INDUSTRY"},"briefTitle":"STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity","officialTitle":"Effect and Safety of Semaglutide Once-weekly in East Asian Subjects With Overweight or Obesity","acronym":"STEP 6"},"statusModule":{"statusVerifiedDate":"2022-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-01-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-11-20","type":"ACTUAL"},"completionDateStruct":{"date":"2020-11-20","type":"ACTUAL"},"studyFirstSubmitDate":"2019-01-18","studyFirstSubmitQcDate":"2019-01-18","studyFirstPostDateStruct":{"date":"2019-01-22","type":"ACTUAL"},"resultsFirstSubmitDate":"2021-11-17","resultsFirstSubmitQcDate":"2022-02-23","resultsFirstPostDateStruct":{"date":"2022-03-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-02-23","lastUpdatePostDateStruct":{"date":"2022-03-22","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novo Nordisk A/S","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"This study will look at the change in participants' body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking \"dummy\" medicine. In addition to taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight. Participants will either get semaglutide or \"dummy\" medicine - which treatment participants get is decided by chance. Participants are three times as likely to get semaglutide as \"dummy\" medicine. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skinfold in the stomach, thigh or upper arm. The study will last for about one and a half years. Participants will have 14 clinic visits and 11 phone calls with the study doctor."},"conditionsModule":{"conditions":["Overweight","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"Sponsor staff involved in the clinical trial is masked according to company standard procedures","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":401,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Semaglutide 2.4 mg","type":"EXPERIMENTAL","description":"Participants will receive semaglutide injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), until the target dose (2.4 mg) is reached after 16 weeks. Participants will continue semaglutide 2.4 mg until week 68.","interventionNames":["Drug: Semaglutide"]},{"label":"Placebo (semaglutide 2.4 mg)","type":"PLACEBO_COMPARATOR","description":"Participants will receive placebo (semaglutide) injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), until the target dose (2.4 mg) is reached after 16 weeks. Participants will continue placebo (semaglutide 2.4 mg) until week 68.","interventionNames":["Drug: Placebo (semaglutide)"]},{"label":"Semaglutide 1.7 mg","type":"EXPERIMENTAL","description":"Participants will receive semaglutide injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), until the target dose (1.7 mg) is reached after 12 weeks. Participants will continue semaglutide 1.7 mg until week 68.","interventionNames":["Drug: Semaglutide"]},{"label":"Placebo (semaglutide 1.7 mg)","type":"PLACEBO_COMPARATOR","description":"Participants will receive placebo (semaglutide) injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), until the target dose (1.7 mg) is reached after 12 weeks. Participants will continue placebo (semaglutide 1.7) until week 68.","interventionNames":["Drug: Placebo (semaglutide)"]}],"interventions":[{"type":"DRUG","name":"Semaglutide","description":"Semaglutide injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.","armGroupLabels":["Semaglutide 1.7 mg","Semaglutide 2.4 mg"]},{"type":"DRUG","name":"Placebo (semaglutide)","description":"Placebo (semaglutide) injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.","armGroupLabels":["Placebo (semaglutide 1.7 mg)","Placebo (semaglutide 2.4 mg)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Body Weight (%)","description":"Change from baseline (week 0) in body weight for 'in-trial' observation period at week 68 is presented. In-trial observation period: the uninterrupted time interval from the start of randomisation (week 0) to last trial-related subject-site contact (week 75).","timeFrame":"Baseline (week 0), week 68"},{"measure":"Number of Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 5%","description":"Number of participants who achieved greater than or equal to (≥) 5% weight loss at week 68 for in-trial observation period is presented. In the reported data, 'Yes' infers the number of participants who have achieved ≥ 5% weight loss, whereas 'No' infers the number of participants who have not achieved ≥ 5% weight loss. In-trial observation period: the uninterrupted time interval from the start of randomisation (week 0) to last trial-related subject-site contact (week 75).","timeFrame":"At week 68"}],"secondaryOutcomes":[{"measure":"Number of Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 10%","description":"Number of participants who achieved greater than or equal to (≥) 10% weight loss at week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved ≥ 10% weight loss, whereas 'No' infers the number of participants who have not achieved ≥ 10% weight loss. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"At week 68"},{"measure":"Number of Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 15%","description":"Number of participants who achieved greater than or equal to (≥) 15% weight loss at week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved ≥ 15% weight loss, whereas 'No' infers the number of participants who have not achieved ≥ 15% weight loss. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization to last trial-related subject-site contact.","timeFrame":"At week 68"},{"measure":"Number of Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 20%","description":"Number of participants who achieved greater than or equal to (≥) 20% weight loss at week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved ≥ 20% weight loss, whereas 'No' infers the number of participants who have not achieved ≥ 20% weight loss. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"At week 68"},{"measure":"Change in Waist Circumference Measured Midway Between the Lower Rib Margin and the Iliac Crest","description":"Change in waist circumference measured midway between the lower rib margin and the iliac crest from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Waist Circumference Measured According to the JASSO (Japan Society for the Study of Obesity) Guideline","description":"Change in Waist circumference measured according to the JASSO guideline from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Body Weight (Kg)","description":"Change in body weight from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Body Mass Index (BMI)","description":"Change in BMI from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Visceral Fat Area (VFA) (%)","description":"Change in VFA from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Visceral Fat Area (VFA) Centimeter Square (cm^2)","description":"Change in VFA from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in HbA1c (%)","description":"Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in HbA1c (mmol/Mol)","description":"Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Fasting Plasma Glucose","description":"Change in fasting plasma glucose from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Fasting Serum Insulin-ratio to Baseline","description":"Change in fasting serum insulin measured as milli-international units per milliliter (mIU/mL) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Systolic Blood Pressure","description":"Change in systolic blood pressure from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Diastolic Blood Pressure","description":"Change in diastolic blood pressure from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Total Cholesterol-ratio to Baseline","description":"Change in total cholesterol measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in High-density Lipoproteins (HDL)-Ratio to Baseline","description":"Change in HDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Low-density Lipoproteins (LDL)-Ratio to Baseline","description":"Change in LDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Very Low-density Lipoproteins (VLDL)-Ratio to Baseline","description":"Change in VLDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Free Fatty Acids-ratio to Baseline","description":"Change in free fatty acids measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Triglycerides-ratio to Baseline","description":"Change in triglycerides measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in High Sensitivity C-reactive Protein (hsCRP)-Ratio to Baseline","description":"Change in hsCRP measured in milligram per ilitre (mg/L) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Plasminogen Activator Inhibitor-1 Activity-ratio to Baseline","description":"Change in plasminogen activator inhibitor-1 (PAI-1) activity measured in arbritary units per milliliter (AU/ml) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Short Form 36 v2.0 Acute (SF-36) Score","description":"SF-36 is a 36-item patient-reported survey of patient health that measures participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured eight domains of functional health and well-being as well as 2 component summary scores (physical component summary and mental component summary). This endpoint shows results for all the domains. The 0-100 scale scores from SF-36 were converted to norm-based scores to enable a direct interpretation in relation to distribution of scores in the 2009 U.S. general population. In metric of norm-based scores, 50 and 10 corresponds to mean and standard deviation respectively. Change from week 0 in domain scores and component summary scores were evaluated at week 68. A positive change score indicates an improvement since baseline. These endpoints were evaluated based on data from in-trial observation period which is uninterrupted time interval from randomisation to last contact with trial site.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Impact of Weight on Quality of Life-lite for Clinical Trials (IWQOL-Lite for CT) Score","description":"The Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite-CT) is designed to assess the impact of changes in weight on patients' quality of life within the context of clinical trials. IWQOL-Lite-CT is a 20-item questionnaire-based instrument used to assess the impact of body weight changes on participant's overall health-related quality of life (HRQoL). All IWQOL-Lite-CT composite scores range from 0 to 100, with higher scores reflecting better levels of functioning. This endpoint shows results for 'physical function score' physical and psychosocial domains, and for total'. The endpoint was evaluated based on the data from in-trial observation period which is the uninterrupted time interval from randomisation to last contact with trial site.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Number of Participants Who Achieve (Yes/no): Responder Definition Value for SF-36 Physical Functioning Score","description":"The number of participants experiencing a meaningful within participant improvement in SF-36 Physical function after 68 weeks was determined based on 3.7 threshold. The threshold of 3.7 is specific for overweight or obese population included in the study and calculated using patient global rating anchor questionnaires to reflect participants' own perspective based on Food and Drug Administration (FDA) recommendations. In the reported data, \"Yes\" infers the number of participants who have achieved an improvement in score greater than or equal to the threshold and \"No\" infers number of participants who have not achieved an improvement in score greater than or equal to the threshold. The endpoint was evaluated based on in-trial observation period which is the uninterrupted time interval from randomisation to last contact with trial site.","timeFrame":"At week 68"},{"measure":"Number of Participants Who Achieve (Yes/no): Responder Definition Value for IWQoL-Lite for CT Physical Function (5-items) Score","description":"The number of participants experiencing a meaningful within participant improvement in IWQOL-Lite-CT physical function after 68 weeks was determined based on thresholds of 14.6. The threshold of 14.6 is specific for the population with overweight or obesity included in the study and calculated using patient global rating anchor questionnaires to reflect participants' own perspective based on FDA recommendations. In the reported data, \"Yes\" infers the number of participants who have achieved an improvement in score greater than or equal to the threshold and \"No\" infers the number of participants who have not achieved an improvement in score greater than or equal to the threshold. The endpoint was evaluated based on in-trial observation period which is the uninterrupted time interval from randomisation to last contact with trial site.","timeFrame":"At week 68"},{"measure":"Number of Participants Who Achieved (Yes/no): HbA1c <7.0% (53 mmol/Mol)","description":"Number of participants who achieved HbA1c \\<7% (53 mmol/mol) at week 68 is presented. In the reported data, \"Yes\" infers the number of participants who have achieved HbA1c values less than the 7% and \"No\" infers the number of participants who have not achieved HbA1c values less than the 7%. The endpoint was evaluated based on the data from in-trial observation period which was defined as the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"At week 68"},{"measure":"Number of Participants Who Achieved (Yes/no): HbA1c ≤6.5% (48 mmol/Mol)","description":"Number of participants who achieved HbA1c ≤6.5% (48 mmol/mol) at week 68 is presented. In the reported data, \"Yes\" infers the number of participants who have achieved HbA1c values less than or equal to 6.5% and \"No\" infers the number of participants who have not achieved HbA1c values less than or equal to 6.5%. The endpoint was evaluated based on the data from in-trial observation period which was defined as the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","timeFrame":"At week 68"},{"measure":"Number of Treatment-emergent AEs","description":"An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. All AEs mentioned here are treatment emergent adverse events (TEAE) defined as an event with onset during the on-treatment observation period. On-treatment observation period: the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 68) plus a 7 week follow-up period and excluding any off-treatment time intervals. Off-treatment time interval: time period with at least two consecutive missed doses.","timeFrame":"Week 0 to week 75"},{"measure":"Number of Serious Adverse Events","description":"A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. SAE results occurred from week 0 to week 75 is presented based on the on-treatment observation, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 68) plus a 7 week follow-up period and excluding any off-treatment time intervals. Off-treatment time interval: time period with at least two consecutive missed doses.","timeFrame":"Week 0 to week 75"},{"measure":"Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemia Episodes","description":"Hypoglycaemic episodes with onset during on-treatment observation period were considered treatment-emergent. Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemia episodes with onset during on-treatment observation period were presented. Severe hypoglycaemia: episode requiring assistance of another person to administer carbohydrate, glucagon or take other corrective actions. plasma glucose (PG) concentrations may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by low PG concentration. BG confirmed symptomatic hypoglycaemia: episode that is BG confirmed by PG value \\<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. On-treatment observation period is interval from date of first trial product administration (week 0) to date of last trial product administration (week 68) plus 7-week follow-up period and excluding any off-treatment time intervals.","timeFrame":"Week 0 to week 75"},{"measure":"Change in Pulse","description":"Change in pulse from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 68) plus a 7 week follow-up period and excluding any off-treatment time intervals.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Amylase: Ratio to Baseline","description":"Change in amylase measured in units/liter (U/L) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 68) plus a 7 week follow-up period and excluding any off-treatment time intervals.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Lipase: Ratio to Baseline","description":"Change in lipase measured in units/litre (U/L) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 68) plus a 7 week follow-up period and excluding any off-treatment time intervals.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in Calcitonin: Ratio to Baseline","description":"Change in calcitonin measured in nanogram/litre (ng/L) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 68) plus a 7 week follow-up period and excluding any off-treatment time intervals.","timeFrame":"Baseline (week 0) to week 68"},{"measure":"Change in QTCF Interval","description":"Change in QTCF Interval from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 68) plus a 7 week follow-up period and excluding any off-treatment time intervals.","timeFrame":"Baseline (week 0) to week 68"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, age more than or equal to 18 years at the time of signing informed consent\n* BMI more than or equal to 27.0 kg/m\\^2 with more than or equal to 2 weight related comorbidities (treated or untreated) or BMI more than or equal to 35.0 kg/m\\^2 with more than or equal to 1 weight related comorbidity (treated or untreated) according to the JASSO guideline. At least one comorbidity should be hypertension or dyslipidaemia (Japan only: or T2D)\n* History of at least one self-reported unsuccessful dietary effort to lose body weight\n* For subjects with T2D at screening (Japan only): a) Diagnosed with T2D more than or equal to 180 days prior to the day of screening. b) HbA1c 7.0-10.0% (53-86 mmol/mol) (both inclusive)\n\nExclusion Criteria:\n\n* A self-reported change in body weight more than 5 kg (11 lbs) within 90 days before screening irrespective of medical records\n* For subjects without T2D at screening: HbA1c more than or equal to 48 mmol/mol (6.5%) as measured by the central laboratory at screening\n* For subjects with T2D at screening (Japan only): a) Renal impairment measured as estimated glomerular filtration rate (eGFR) value of less than 30 mL/min/1.73 m\\^2 (less than 60 mL/min/1.73 m\\^2 in subjects treated with sodium-glucose co-transporter 2 inhibitor (SGLT2i)) according to chronic kidney disease epidemiology (CKD-EPI) creatinine equation as defined by kidney disease improving global outcome (KDIGO) 2012 by the central laboratory at screening. b) Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a pharmacologically pupil-dilated fundus examination performed by an ophthalmologist or another suitably qualified health care provider within the past 90 days prior to screening or in the period between screening and randomisation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Reporting Anchor and Disclosure (1452)","affiliation":"Novo Nordisk A/S","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Novo Nordisk Investigational Site","city":"Adachi-ku, Tokyo","zip":"123-0845","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Novo Nordisk Investigational Site","city":"Bunkyo-ku, Tokyo","zip":"113-8655","country":"Japan"},{"facility":"Novo Nordisk Investigational Site","city":"Chitose, Hokkaido","zip":"066-0032","country":"Japan","geoPoint":{"lat":42.81944,"lon":141.65222}},{"facility":"Novo Nordisk Investigational Site","city":"Chuo-ku, Tokyo","zip":"103-0002","country":"Japan"},{"facility":"Novo Nordisk Investigational Site","city":"Chuo-ku,Tokyo","zip":"103-0025","country":"Japan"},{"facility":"Novo Nordisk Investigational Site","city":"Gunma","zip":"373-0036","country":"Japan"},{"facility":"Novo Nordisk Investigational Site","city":"Ibaraki","zip":"311-0113","country":"Japan","geoPoint":{"lat":34.81641,"lon":135.56828}},{"facility":"Novo Nordisk Investigational Site","city":"Kanagawa","zip":"232-0064","country":"Japan","geoPoint":{"lat":37.58333,"lon":139.91667}},{"facility":"Novo Nordisk Investigational Site","city":"Kashiwara-shi, Osaka","zip":"582-0005","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Novo Nordisk Investigational Site","city":"Kobe, Hyogo","zip":"650-0017","country":"Japan"},{"facility":"Novo Nordisk Investigational Site","city":"Kumamoto","zip":"862-0976","country":"Japan","geoPoint":{"lat":32.80589,"lon":130.69181}},{"facility":"Novo Nordisk Investigational Site","city":"Miyazaki","zip":"880-0034","country":"Japan","geoPoint":{"lat":31.91667,"lon":131.41667}},{"facility":"Novo Nordisk Investigational Site","city":"Sapporo-shi, Hokkaido","zip":"004-0004","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"Novo Nordisk Investigational Site","city":"Shimotsuke-shi, Tochigi","zip":"329-0433","country":"Japan","geoPoint":{"lat":36.38333,"lon":139.73333}},{"facility":"Novo Nordisk Investigational Site","city":"Suita-shi, Osaka","zip":"565-0853","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Novo Nordisk Investigational Site","city":"Tokyo","zip":"103-0027","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Novo Nordisk Investigational Site","city":"Tokyo","zip":"103-0028","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Novo Nordisk Investigational Site","city":"Tokyo","zip":"104-0031","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Novo Nordisk Investigational Site","city":"Tokyo","zip":"125-0054","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Novo Nordisk Investigational Site","city":"Tokyo","zip":"160-0008","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Novo Nordisk Investigational Site","city":"Toyama-shi, Toyama","zip":"930-0194","country":"Japan"},{"facility":"Novo Nordisk Investigational Site","city":"Yamato-shi, Kanagawa","zip":"242-0004","country":"Japan","geoPoint":{"lat":37.58333,"lon":139.91667}},{"facility":"Novo Nordisk Investigational Site","city":"Gyeonggi-do","zip":"13620","country":"South Korea","geoPoint":{"lat":37.58944,"lon":126.76917}},{"facility":"Novo Nordisk Investigational Site","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Novo Nordisk Investigational Site","city":"Seoul","zip":"06273","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Novo Nordisk Investigational Site","city":"Seoul","zip":"06351","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Novo Nordisk Investigational Site","city":"Seoul","zip":"06591","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Novo Nordisk Investigational Site","city":"Yangsan","zip":"626-770","country":"South Korea","geoPoint":{"lat":35.34199,"lon":129.03358}}]},"referencesModule":{"references":[{"pmid":"33667417","type":"RESULT","citation":"Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0. Epub 2021 Mar 2."},{"pmid":"40189961","type":"DERIVED","citation":"Kadowaki T, Nishida T, Ogawa W, Overvad M, Tobe K, Yamauchi T. Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial. Obes Res Clin Pract. 2025 Mar-Apr;19(2):146-153. doi: 10.1016/j.orcp.2025.03.003. Epub 2025 Apr 4."},{"pmid":"35131037","type":"DERIVED","citation":"Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, Tobe K, Yamauchi T, Lim S; STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022 Mar;10(3):193-206. doi: 10.1016/S2213-8587(22)00008-0. Epub 2022 Feb 4."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"According to the Novo Nordisk disclosure commitment on novonordisk-trials.com","url":"https://www.novonordisk-trials.com"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"The trial has a 68-week treatment period (12 weeks of dose escalation and 56 weeks of maintenance dose for 1.7 milligram (mg) once weekly arm and 16 weeks of dose escalation and 52 weeks of maintenance dose for 2.4 mg once weekly arm). Participants were randomised in 4:1:2:1 ratio to receive either semaglutide subcutaneously (s.c.) 2.4 mg once-weekly, semaglutide placebo once-weekly, semaglutide s.c. 1.7 mg once-weekly or semaglutide placebo once-weekly.","recruitmentDetails":"The trial was conducted at 28 sites in 2 countries as follows (all sites screened and randomized):Japan (22 sites) and South korea (6 sites).","groups":[{"id":"FG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 milliliter (mL) cartridge containing semaglutide 1.0 milligram per milliliter (mg/mL) or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"FG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"FG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"101"},{"groupId":"FG001","numSubjects":"199"},{"groupId":"FG002","numSubjects":"101"}]},{"type":"Full Analysis Set (FAS)","achievements":[{"groupId":"FG000","numSubjects":"101"},{"groupId":"FG001","numSubjects":"199"},{"groupId":"FG002","numSubjects":"101"}]},{"type":"Safety Analysis Set (SAS)","achievements":[{"groupId":"FG000","numSubjects":"100"},{"groupId":"FG001","numSubjects":"199"},{"groupId":"FG002","numSubjects":"101"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"100"},{"groupId":"FG001","numSubjects":"199"},{"groupId":"FG002","numSubjects":"101"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"99"},{"groupId":"FG001","numSubjects":"195"},{"groupId":"FG002","numSubjects":"101"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Full analysis set (FAS) included all randomised participants.","groups":[{"id":"BG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"BG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"BG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"199"},{"groupId":"BG002","value":"101"},{"groupId":"BG003","value":"401"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"51","spread":"10"},{"groupId":"BG001","value":"52","spread":"12"},{"groupId":"BG002","value":"50","spread":"9"},{"groupId":"BG003","value":"51","spread":"11"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"148"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"114"},{"groupId":"BG002","value":"75"},{"groupId":"BG003","value":"253"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"199"},{"groupId":"BG002","value":"101"},{"groupId":"BG003","value":"401"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"199"},{"groupId":"BG002","value":"101"},{"groupId":"BG003","value":"401"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Body Weight (%)","description":"Change from baseline (week 0) in body weight for 'in-trial' observation period at week 68 is presented. In-trial observation period: the uninterrupted time interval from the start of randomisation (week 0) to last trial-related subject-site contact (week 75).","populationDescription":"FAS which comprised all randomised participants. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage change","timeFrame":"Baseline (week 0), week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.9","spread":"7.8"},{"groupId":"OG001","value":"-13.4","spread":"8.6"},{"groupId":"OG002","value":"-1.9","spread":"5.9"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Treatment policy estimand","nonInferiorityType":"SUPERIORITY","pValue":"<.0001","statisticalMethod":"ANCOVA","paramType":"Treatment difference","paramValue":"-7.52","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.62","ciUpperLimit":"-5.43"},{"groupIds":["OG001","OG002"],"groupDescription":"Treatment policy estimand","nonInferiorityType":"SUPERIORITY","pValue":"<.0001","statisticalMethod":"ANCOVA","paramType":"Treatment difference","paramValue":"-11.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-12.88","ciUpperLimit":"-9.24"}]},{"type":"PRIMARY","title":"Number of Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 5%","description":"Number of participants who achieved greater than or equal to (≥) 5% weight loss at week 68 for in-trial observation period is presented. In the reported data, 'Yes' infers the number of participants who have achieved ≥ 5% weight loss, whereas 'No' infers the number of participants who have not achieved ≥ 5% weight loss. In-trial observation period: the uninterrupted time interval from the start of randomisation (week 0) to last trial-related subject-site contact (week 75).","populationDescription":"FAS which comprised all randomised participants. Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"100"}]}],"classes":[{"categories":[{"title":"Yes","measurements":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"21"}]},{"title":"No","measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"79"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Treatment policy estimand","nonInferiorityType":"SUPERIORITY","pValue":"<.0001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"11.08","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"5.53","ciUpperLimit":"22.22"},{"groupIds":["OG001","OG002"],"groupDescription":"Treatment policy estimand","nonInferiorityType":"SUPERIORITY","pValue":"<.0001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"21.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"11.27","ciUpperLimit":"41.86"}]},{"type":"SECONDARY","title":"Number of Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 10%","description":"Number of participants who achieved greater than or equal to (≥) 10% weight loss at week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved ≥ 10% weight loss, whereas 'No' infers the number of participants who have not achieved ≥ 10% weight loss. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS which comprised all randomized participants. Overall number of participants analyzed = participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"100"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"117"},{"groupId":"OG002","value":"5"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"95"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 15%","description":"Number of participants who achieved greater than or equal to (≥) 15% weight loss at week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved ≥ 15% weight loss, whereas 'No' infers the number of participants who have not achieved ≥ 15% weight loss. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization to last trial-related subject-site contact.","populationDescription":"FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"100"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"3"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"114"},{"groupId":"OG002","value":"97"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 20%","description":"Number of participants who achieved greater than or equal to (≥) 20% weight loss at week 68 is presented. In the reported data, 'Yes' infers the number of participants who have achieved ≥ 20% weight loss, whereas 'No' infers the number of participants who have not achieved ≥ 20% weight loss. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS which comprised all randomised participants. Overall number of participants analyzed = participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"100"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"2"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"155"},{"groupId":"OG002","value":"98"}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference Measured Midway Between the Lower Rib Margin and the Iliac Crest","description":"Change in waist circumference measured midway between the lower rib margin and the iliac crest from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Centimeter (cm)","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.8","spread":"6.9"},{"groupId":"OG001","value":"-11.2","spread":"7.5"},{"groupId":"OG002","value":"-1.8","spread":"5.9"}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference Measured According to the JASSO (Japan Society for the Study of Obesity) Guideline","description":"Change in Waist circumference measured according to the JASSO guideline from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Centimeter (cm)","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.6","spread":"5.7"},{"groupId":"OG001","value":"-10.2","spread":"6.8"},{"groupId":"OG002","value":"-1.9","spread":"5.3"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (Kg)","description":"Change in body weight from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Kilogram (kg)","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.3","spread":"6.1"},{"groupId":"OG001","value":"-11.3","spread":"7.3"},{"groupId":"OG002","value":"-1.7","spread":"5.6"}]}]}]},{"type":"SECONDARY","title":"Change in Body Mass Index (BMI)","description":"Change in BMI from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Kilogram per square meter (kg/m^2)","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"2.4"},{"groupId":"OG001","value":"-4.3","spread":"2.8"},{"groupId":"OG002","value":"-0.6","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Change in Visceral Fat Area (VFA) (%)","description":"Change in VFA from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"CT scan subpopulation included all randomised participants who had a CT scan assessment. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage change","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.3","spread":"31.3"},{"groupId":"OG001","value":"-41.0","spread":"23.3"},{"groupId":"OG002","value":"-7.1","spread":"19.5"}]}]}]},{"type":"SECONDARY","title":"Change in Visceral Fat Area (VFA) Centimeter Square (cm^2)","description":"Change in VFA from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"CT scan subpopulation included all randomised participants who had a CT scan assessment. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"centimeter square (cm^2)","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.7","spread":"47.0"},{"groupId":"OG001","value":"-67.4","spread":"43.0"},{"groupId":"OG002","value":"-13.8","spread":"38.6"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c (%)","description":"Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage of HbA1c","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.8"},{"groupId":"OG001","value":"-1.0","spread":"1.0"},{"groupId":"OG002","value":"0.0","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c (mmol/Mol)","description":"Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"millimoles per mole (mmol/mol)","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.9","spread":"8.9"},{"groupId":"OG001","value":"-10.6","spread":"10.4"},{"groupId":"OG002","value":"-0.1","spread":"8.3"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose","description":"Change in fasting plasma glucose from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Milligrams per deciliter (mg/dL)","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.3","spread":"21.9"},{"groupId":"OG001","value":"-19.3","spread":"22.6"},{"groupId":"OG002","value":"1.7","spread":"26.1"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Serum Insulin-ratio to Baseline","description":"Change in fasting serum insulin measured as milli-international units per milliliter (mIU/mL) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of fasting serum insulin","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"190"},{"groupId":"OG002","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":"65"},{"groupId":"OG001","value":"0.71","spread":"57.7"},{"groupId":"OG002","value":"0.89","spread":"49.4"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure","description":"Change in systolic blood pressure from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"millimeters of mercury (mmHg)","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12","spread":"13"},{"groupId":"OG001","value":"-11","spread":"15"},{"groupId":"OG002","value":"-5","spread":"15"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure","description":"Change in diastolic blood pressure from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":"10"},{"groupId":"OG001","value":"-5","spread":"10"},{"groupId":"OG002","value":"-3","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Change in Total Cholesterol-ratio to Baseline","description":"Change in total cholesterol measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of total cholesterol","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"16.5"},{"groupId":"OG001","value":"0.91","spread":"13.3"},{"groupId":"OG002","value":"1.00","spread":"12.7"}]}]}]},{"type":"SECONDARY","title":"Change in High-density Lipoproteins (HDL)-Ratio to Baseline","description":"Change in HDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of high-density lipoproteins","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":"17.3"},{"groupId":"OG001","value":"1.08","spread":"13.7"},{"groupId":"OG002","value":"1.06","spread":"12.1"}]}]}]},{"type":"SECONDARY","title":"Change in Low-density Lipoproteins (LDL)-Ratio to Baseline","description":"Change in LDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of low-density lipoproteins","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"99"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":"25.2"},{"groupId":"OG001","value":"0.86","spread":"23.5"},{"groupId":"OG002","value":"0.95","spread":"21.1"}]}]}]},{"type":"SECONDARY","title":"Change in Very Low-density Lipoproteins (VLDL)-Ratio to Baseline","description":"Change in VLDL measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomization to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of very low-density lipoproteins","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"99"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.79","spread":"43.2"},{"groupId":"OG001","value":"0.79","spread":"43.2"},{"groupId":"OG002","value":"1.05","spread":"41.2"}]}]}]},{"type":"SECONDARY","title":"Change in Free Fatty Acids-ratio to Baseline","description":"Change in free fatty acids measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of free fatty acids","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"190"},{"groupId":"OG002","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":"57.7"},{"groupId":"OG001","value":"0.96","spread":"59.1"},{"groupId":"OG002","value":"1.28","spread":"52.6"}]}]}]},{"type":"SECONDARY","title":"Change in Triglycerides-ratio to Baseline","description":"Change in triglycerides measured as milligrams per deciliter (mg/dL) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of triglycerides","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"99"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":"49.8"},{"groupId":"OG001","value":"0.79","spread":"43.8"},{"groupId":"OG002","value":"1.05","spread":"41.0"}]}]}]},{"type":"SECONDARY","title":"Change in High Sensitivity C-reactive Protein (hsCRP)-Ratio to Baseline","description":"Change in hsCRP measured in milligram per ilitre (mg/L) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of hsCRP","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"193"},{"groupId":"OG002","value":"100"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.64","spread":"218.3"},{"groupId":"OG001","value":"0.39","spread":"119.3"},{"groupId":"OG002","value":"0.92","spread":"123"}]}]}]},{"type":"SECONDARY","title":"Change in Plasminogen Activator Inhibitor-1 Activity-ratio to Baseline","description":"Change in plasminogen activator inhibitor-1 (PAI-1) activity measured in arbritary units per milliliter (AU/ml) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analyzed' = participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of PAI-1 activity","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"190"},{"groupId":"OG002","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"75.8"},{"groupId":"OG001","value":"0.68","spread":"62"},{"groupId":"OG002","value":"1","spread":"51.8"}]}]}]},{"type":"SECONDARY","title":"Change in Short Form 36 v2.0 Acute (SF-36) Score","description":"SF-36 is a 36-item patient-reported survey of patient health that measures participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured eight domains of functional health and well-being as well as 2 component summary scores (physical component summary and mental component summary). This endpoint shows results for all the domains. The 0-100 scale scores from SF-36 were converted to norm-based scores to enable a direct interpretation in relation to distribution of scores in the 2009 U.S. general population. In metric of norm-based scores, 50 and 10 corresponds to mean and standard deviation respectively. Change from week 0 in domain scores and component summary scores were evaluated at week 68. A positive change score indicates an improvement since baseline. These endpoints were evaluated based on data from in-trial observation period which is uninterrupted time interval from randomisation to last contact with trial site.","populationDescription":"FAS included all randomised participants. Overall Number of Participants Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"100"}]}],"classes":[{"title":"Change in SF-36:Physical functioning score","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"5.7"},{"groupId":"OG001","value":"1.0","spread":"3.7"},{"groupId":"OG002","value":"-0.5","spread":"3.9"}]}]},{"title":"Change in SF-36: Role-Physical score","categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"5.2"},{"groupId":"OG001","value":"-0.2","spread":"4.7"},{"groupId":"OG002","value":"0.3","spread":"5.8"}]}]},{"title":"Change in SF-36: Bodily Pain score","categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"9.2"},{"groupId":"OG001","value":"-1.1","spread":"7.5"},{"groupId":"OG002","value":"-0.2","spread":"8.8"}]}]},{"title":"Change in SF-36: General Health score","categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"5.4"},{"groupId":"OG001","value":"0.4","spread":"5.8"},{"groupId":"OG002","value":"-0.6","spread":"5.6"}]}]},{"title":"Change in SF-36: Vitality score","categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"7.8"},{"groupId":"OG001","value":"-1.5","spread":"6.8"},{"groupId":"OG002","value":"-0.9","spread":"7.4"}]}]},{"title":"Change in SF-36: Social Functioning score","categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"3.8"},{"groupId":"OG001","value":"-0.9","spread":"6.2"},{"groupId":"OG002","value":"0.3","spread":"5.6"}]}]},{"title":"Change in SF-36: Role-Emotional score","categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"5.6"},{"groupId":"OG001","value":"-1.1","spread":"5.5"},{"groupId":"OG002","value":"-0.9","spread":"4.1"}]}]},{"title":"Change in SF-36: Mental Health score","categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"7.2"},{"groupId":"OG001","value":"-1.5","spread":"6.7"},{"groupId":"OG002","value":"-1.2","spread":"5.2"}]}]},{"title":"Change in SF-36: Physical component summary","categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"6.0"},{"groupId":"OG001","value":"0.7","spread":"4.4"},{"groupId":"OG002","value":"0.1","spread":"5.3"}]}]},{"title":"Change in SF-36: Mental component summary","categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"6.4"},{"groupId":"OG001","value":"-1.9","spread":"6.4"},{"groupId":"OG002","value":"-1.0","spread":"4.7"}]}]}]},{"type":"SECONDARY","title":"Change in Impact of Weight on Quality of Life-lite for Clinical Trials (IWQOL-Lite for CT) Score","description":"The Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite-CT) is designed to assess the impact of changes in weight on patients' quality of life within the context of clinical trials. IWQOL-Lite-CT is a 20-item questionnaire-based instrument used to assess the impact of body weight changes on participant's overall health-related quality of life (HRQoL). All IWQOL-Lite-CT composite scores range from 0 to 100, with higher scores reflecting better levels of functioning. This endpoint shows results for 'physical function score' physical and psychosocial domains, and for total'. The endpoint was evaluated based on the data from in-trial observation period which is the uninterrupted time interval from randomisation to last contact with trial site.","populationDescription":"FAS included all randomised participants. Overall Number of Participants Analyzed = number of participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"100"}]}],"classes":[{"title":"Physical function score","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"16.3"},{"groupId":"OG001","value":"4.9","spread":"15.1"},{"groupId":"OG002","value":"0.5","spread":"12.7"}]}]},{"title":"Physical","categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"14.3"},{"groupId":"OG001","value":"4.2","spread":"14.4"},{"groupId":"OG002","value":"-0.8","spread":"11.3"}]}]},{"title":"Psychosocial","categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"11.9"},{"groupId":"OG001","value":"5.2","spread":"12.7"},{"groupId":"OG002","value":"-0.3","spread":"12.1"}]}]},{"title":"Total","categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"11.0"},{"groupId":"OG001","value":"4.8","spread":"11.8"},{"groupId":"OG002","value":"-0.5","spread":"10.3"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieve (Yes/no): Responder Definition Value for SF-36 Physical Functioning Score","description":"The number of participants experiencing a meaningful within participant improvement in SF-36 Physical function after 68 weeks was determined based on 3.7 threshold. The threshold of 3.7 is specific for overweight or obese population included in the study and calculated using patient global rating anchor questionnaires to reflect participants' own perspective based on Food and Drug Administration (FDA) recommendations. In the reported data, \"Yes\" infers the number of participants who have achieved an improvement in score greater than or equal to the threshold and \"No\" infers number of participants who have not achieved an improvement in score greater than or equal to the threshold. The endpoint was evaluated based on in-trial observation period which is the uninterrupted time interval from randomisation to last contact with trial site.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analysed' = participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"100"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"13"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"149"},{"groupId":"OG002","value":"87"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieve (Yes/no): Responder Definition Value for IWQoL-Lite for CT Physical Function (5-items) Score","description":"The number of participants experiencing a meaningful within participant improvement in IWQOL-Lite-CT physical function after 68 weeks was determined based on thresholds of 14.6. The threshold of 14.6 is specific for the population with overweight or obesity included in the study and calculated using patient global rating anchor questionnaires to reflect participants' own perspective based on FDA recommendations. In the reported data, \"Yes\" infers the number of participants who have achieved an improvement in score greater than or equal to the threshold and \"No\" infers the number of participants who have not achieved an improvement in score greater than or equal to the threshold. The endpoint was evaluated based on in-trial observation period which is the uninterrupted time interval from randomisation to last contact with trial site.","populationDescription":"FAS included all randomised participants. 'Overall Number of Participants Analysed' = participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"100"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"11"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"143"},{"groupId":"OG002","value":"89"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieved (Yes/no): HbA1c <7.0% (53 mmol/Mol)","description":"Number of participants who achieved HbA1c \\<7% (53 mmol/mol) at week 68 is presented. In the reported data, \"Yes\" infers the number of participants who have achieved HbA1c values less than the 7% and \"No\" infers the number of participants who have not achieved HbA1c values less than the 7%. The endpoint was evaluated based on the data from in-trial observation period which was defined as the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. Overall Number of Participants Analyzed = participants with type 2 diabetes at screening with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"25"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"1"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"24"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieved (Yes/no): HbA1c ≤6.5% (48 mmol/Mol)","description":"Number of participants who achieved HbA1c ≤6.5% (48 mmol/mol) at week 68 is presented. In the reported data, \"Yes\" infers the number of participants who have achieved HbA1c values less than or equal to 6.5% and \"No\" infers the number of participants who have not achieved HbA1c values less than or equal to 6.5%. The endpoint was evaluated based on the data from in-trial observation period which was defined as the uninterrupted time interval from the start of randomisation to last trial-related subject-site contact.","populationDescription":"FAS included all randomised participants. Overall Number of Participants Analyzed = participants with type 2 diabetes at screening with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"25"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"1"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"24"}]}]}]},{"type":"SECONDARY","title":"Number of Treatment-emergent AEs","description":"An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. All AEs mentioned here are treatment emergent adverse events (TEAE) defined as an event with onset during the on-treatment observation period. On-treatment observation period: the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 68) plus a 7 week follow-up period and excluding any off-treatment time intervals. Off-treatment time interval: time period with at least two consecutive missed doses.","populationDescription":"Safety analysis set (SAS) included all randomised participants exposed to at least one dose of randomised treatment.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events","timeFrame":"Week 0 to week 75","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"199"},{"groupId":"OG002","value":"101"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"483"},{"groupId":"OG001","value":"834"},{"groupId":"OG002","value":"235"}]}]}]},{"type":"SECONDARY","title":"Number of Serious Adverse Events","description":"A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. SAE results occurred from week 0 to week 75 is presented based on the on-treatment observation, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 68) plus a 7 week follow-up period and excluding any off-treatment time intervals. Off-treatment time interval: time period with at least two consecutive missed doses.","populationDescription":"Safety analysis set (SAS) included all randomised participants exposed to at least one dose of randomised treatment.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events","timeFrame":"Week 0 to week 75","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"199"},{"groupId":"OG002","value":"101"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"7"}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemia Episodes","description":"Hypoglycaemic episodes with onset during on-treatment observation period were considered treatment-emergent. Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemia episodes with onset during on-treatment observation period were presented. Severe hypoglycaemia: episode requiring assistance of another person to administer carbohydrate, glucagon or take other corrective actions. plasma glucose (PG) concentrations may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by low PG concentration. BG confirmed symptomatic hypoglycaemia: episode that is BG confirmed by PG value \\<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. On-treatment observation period is interval from date of first trial product administration (week 0) to date of last trial product administration (week 68) plus 7-week follow-up period and excluding any off-treatment time intervals.","populationDescription":"Safety analysis set (SAS) included all randomised participants exposed to at least one dose of randomised treatment. Overall number of participants analyzed = participants with type 2 diabetes at screening.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Episodes","timeFrame":"Week 0 to week 75","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Change in Pulse","description":"Change in pulse from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 68) plus a 7 week follow-up period and excluding any off-treatment time intervals.","populationDescription":"SAS included all randomised participants exposed to at least one dose of randomised treatment. 'Overall Number of Participants Analysed' = participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Beats/minute","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":"10"},{"groupId":"OG001","value":"4","spread":"9"},{"groupId":"OG002","value":"2","spread":"10"}]}]}]},{"type":"SECONDARY","title":"Change in Amylase: Ratio to Baseline","description":"Change in amylase measured in units/liter (U/L) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 68) plus a 7 week follow-up period and excluding any off-treatment time intervals.","populationDescription":"SAS included all randomised participants exposed to at least one dose of randomised treatment. 'Overall Number of Participants Analysed' = participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of amylase","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":"20.9"},{"groupId":"OG001","value":"1.08","spread":"23.2"},{"groupId":"OG002","value":"0.93","spread":"25.1"}]}]}]},{"type":"SECONDARY","title":"Change in Lipase: Ratio to Baseline","description":"Change in lipase measured in units/litre (U/L) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 68) plus a 7 week follow-up period and excluding any off-treatment time intervals.","populationDescription":"SAS included all randomised participants exposed to at least one dose of randomised treatment. 'Overall Number of Participants Analysed' = participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of lipase","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.56","spread":"39.8"},{"groupId":"OG001","value":"1.56","spread":"45.4"},{"groupId":"OG002","value":"0.96","spread":"40.5"}]}]}]},{"type":"SECONDARY","title":"Change in Calcitonin: Ratio to Baseline","description":"Change in calcitonin measured in nanogram/litre (ng/L) from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 68) plus a 7 week follow-up period and excluding any off-treatment time intervals.","populationDescription":"SAS included all randomised participants exposed to at least one dose of randomised treatment. 'Overall Number of Participants Analysed' = participants with available data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio of calcitonin","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"98"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"32.4"},{"groupId":"OG001","value":"0.95","spread":"34.6"},{"groupId":"OG002","value":"0.94","spread":"30.6"}]}]}]},{"type":"SECONDARY","title":"Change in QTCF Interval","description":"Change in QTCF Interval from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from on-treatment observation period, which was defined as the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 68) plus a 7 week follow-up period and excluding any off-treatment time intervals.","populationDescription":"SAS included all randomised participants exposed to at least one dose of randomised treatment. 'Overall Number of Participants Analysed' = participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"millisecond (msec)","timeFrame":"Baseline (week 0) to week 68","groups":[{"id":"OG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity."},{"id":"OG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"96"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"17.8"},{"groupId":"OG001","value":"-2.5","spread":"15.2"},{"groupId":"OG002","value":"5.6","spread":"14.1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Week 0 to week 75.","description":"All presented AEs are treatment-emergent (i.e., TEAEs). Adverse events were defined as \"treatment-emergent\" (TEAE), if the onset of the event occurs in the on-treatment period. Results are based on the SAS which included all randomised participants exposed to at least one dose of randomised treatment.","eventGroups":[{"id":"EG000","title":"Semaglutide 1.7 mg","description":"Participants were to receive once-weekly subcutaneous (s.c) injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), aiming at reaching the maintenance dose of 1.7 mg once-weekly after 12 weeks. Treatment was continued on the maintenance dose of 1.7 mg once-weekly for an additional 56 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity.","deathsNumAffected":0,"deathsNumAtRisk":100,"seriousNumAffected":7,"seriousNumAtRisk":100,"otherNumAffected":73,"otherNumAtRisk":100},{"id":"EG001","title":"Semaglutide 2.4 mg","description":"Participants were to receive once-weekly s.c. injection of 0.25 mg semaglutide administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), aiming at reaching the maintenance dose of 2.4 mg once-weekly after 16 weeks. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 68. The treatment was an adjunct to a reduced calorie diet and increased physical activity.","deathsNumAffected":0,"deathsNumAtRisk":199,"seriousNumAffected":10,"seriousNumAtRisk":199,"otherNumAffected":142,"otherNumAtRisk":199},{"id":"EG002","title":"Placebo","description":"Participants were to receive once-weekly s.c. injection of placebo matched to semaglutide for 68 weeks.","deathsNumAffected":0,"deathsNumAtRisk":101,"seriousNumAffected":7,"seriousNumAtRisk":101,"otherNumAffected":49,"otherNumAtRisk":101}],"seriousEvents":[{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":101}]},{"term":"Bile duct adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Carpal tunnel syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Clear cell renal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Colitis ischaemic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Diverticulitis Meckel's","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Endometrial hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Infectious mononucleosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":101}]},{"term":"Large intestine polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":101}]},{"term":"Lymphadenitis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Muscle strain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":100},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":101}]},{"term":"Rhabdomyolysis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Rhegmatogenous retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":101}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":100},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":101}]},{"term":"Tendon rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Ureterolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":100},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":101}]}],"otherEvents":[{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":100},{"groupId":"EG001","numEvents":16,"numAffected":12,"numAtRisk":199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":101}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":100},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":199},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":101}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":100},{"groupId":"EG001","numEvents":16,"numAffected":12,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":100},{"groupId":"EG001","numEvents":13,"numAffected":10,"numAtRisk":199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":101}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":100},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":199},{"groupId":"EG002","numEvents":9,"numAffected":6,"numAtRisk":101}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":100},{"groupId":"EG001","numEvents":20,"numAffected":19,"numAtRisk":199},{"groupId":"EG002","numEvents":11,"numAffected":9,"numAtRisk":101}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":19,"numAtRisk":100},{"groupId":"EG001","numEvents":60,"numAffected":52,"numAtRisk":199},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":101}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":100},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":100},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":199},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":101}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":59,"numAffected":22,"numAtRisk":100},{"groupId":"EG001","numEvents":52,"numAffected":32,"numAtRisk":199},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":101}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":100},{"groupId":"EG001","numEvents":19,"numAffected":14,"numAtRisk":199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":101}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":6,"numAtRisk":100},{"groupId":"EG001","numEvents":14,"numAffected":9,"numAtRisk":199},{"groupId":"EG002","numEvents":4,"numAffected":1,"numAtRisk":101}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":100},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":101}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":100},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":199},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":101}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":24,"numAtRisk":100},{"groupId":"EG001","numEvents":81,"numAffected":53,"numAtRisk":199},{"groupId":"EG002","numEvents":24,"numAffected":18,"numAtRisk":101}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":18,"numAtRisk":100},{"groupId":"EG001","numEvents":66,"numAffected":35,"numAtRisk":199},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":101}]},{"term":"Upper respiratory tract inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":100},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":199},{"groupId":"EG002","numEvents":13,"numAffected":9,"numAtRisk":101}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":10,"numAtRisk":100},{"groupId":"EG001","numEvents":29,"numAffected":17,"numAtRisk":199},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":101}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property."},"pointOfContact":{"title":"Clinical Transparency Anchor and Disclosure (1452)","organization":"Novo Nordisk A/S","email":"clinicaltrials@novonordisk.com","phone":"(+1) 866-867-7178"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2018-08-08","uploadDate":"2021-11-17T14:07","filename":"Prot_000.pdf","size":1199058},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2021-03-19","uploadDate":"2021-11-17T05:38","filename":"SAP_001.pdf","size":808246}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2021-12-17","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D050177","term":"Overweight"},{"id":"D009765","term":"Obesity"}],"ancestors":[{"id":"D044343","term":"Overnutrition"},{"id":"D009748","term":"Nutrition Disorders"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"C000591245","term":"semaglutide"}]}},"hasResults":true}